The Blazer Bridge Fund encourages discovery among the UAB community by providing financial support to innovative ideas and inventions.

Kirk Habegger, Ph.D., Professor of Medicine in the UAB Department of Medicine Division of Endocrinology, Diabetes and Metabolism, has received funding from Eli Lilly and Company to continue investigation of glucagon receptor activation in incretin-based obesity therapies.

Ben Gran is the lab manager for both Dr. Rita Basu and Dr.

Health care providers from across the state and region gathered to learn about diabetes, thyroid disorders, osteoporosis, and more at the 2025 UAB Endocrinology Update, Aug. 23, at Hilton Birmingham Downtown at the University of Alabama at Birmingham (UAB).

According to the 2025-2026 rankings released in July, UAB Medicine ranked nationally in five adult specialties and high performing in seven other specialties including diabetes and endocrinology.

A new study led by UAB Comprehensive Diabetes Center Associate Scientist Fernando Bril, M.D., provides the first evidence that MASLD prevalence is beginning to decrease in adults with diabetes in the U.S. for the first time in decades.

The University of Alabama at Birmingham startup TIXiMED, Inc., has successfully completed a Phase 1 single ascending dose study of the drug TIX100 in humans, marking a key milestone in the development of a first-of-its kind oral therapy for Type 1 diabetes (T1D).

UAB Comprehensive Diabetes Center (UCDC) researchers have contributed to the Frontiers in Endocrinology Research Topic on Disease-Modifying Approaches in Type 1 Diabetes.

Ananda Basu, MBBS, MD, FRCP, M.D., has been appointed as an associate director of the UAB Comprehensive Diabetes Center (UCDC) and will play an integral role on the center’s leadership team.

Researchers from the University of Alabama at Birmingham Comprehensive Diabetes Center (UCDC) showcased their latest findings at the 17th Annual Midwest Islet Club (MIC) Meeting, May 7-8, in Indianapolis, Indiana.

A new study led by Ananda Basu, M.D., used novel non-radioactive, stable glucagon tracers for the first time to characterize glucagon metabolism in humans with and without Type 1 diabetes, providing tools for further exploration into pancreatic alpha cell function in both Type 1 and 2 diabetes and other metabolic disorders.

UAB is ranked No. 164 based on exceptional academic research portfolio and its overall global and regional reputation.

Blazer Bridge Fund provides financial support to innovative ideas and inventions by the UAB community, encouraging advanced discovery. 

A cluster analysis in the Deep South showed that racial background significantly influences diabetes subtype distribution.

The novel drug TIX100 functions differently from any approved diabetes drug to promote proper islet cell function.

For 11 consecutive years, U.S. News has named UAB Hospital the best hospital in Alabama, with several specialties and procedures ranked among the best.

This advance should facilitate atherosclerosis drug discovery and development.

Continuous glucose monitors and insulin pumps can help patients “live a quality life without burning out on managing diabetes,” said Ananda Basu, M.D., director of the Diabetes Technology Program at UAB.

UAB diabetes expert serves up tailgating hacks to make football season fun and diabetes-friendly.

These results add an additional, mechanistic aspect to further explain how the decades-old blood pressure medication verapamil can preserve beta cell function in Type 1 diabetes patients by affecting the hormone insulin-like growth factor 1.

In just the five years since UAB completed 10,000 robotic surgeries, surgeons across 15 disciplines have now collectively exceeded 20,000 robotic surgeries, setting a record for the hospital.

Continuous glucose monitors can transform one’s diabetes treatment and care. A UAB diabetes expert explains what patients should know about the devices when evaluating their diabetes care plans.

Continuous glucose monitors are “such a useful and impactful behavior modification tool” that half of his patients with Type 1 and Type 2 diabetes now use these devices, said Fernando Ovalle, M.D., director of UAB’s Multidisciplinary Comprehensive Diabetes Clinic. Learn how data leads to better decisions and better control of diabetes.

Anath Shalev, M.D., did everything she could to change treatment for Type 1 diabetes from her lab, but getting to first-in-human trials meant taking a step she had always resisted. The most surprising thing about launching a startup, though?

UAB’s research and reputation land it among the top institutions in the world.